Monthly Dosing of Consolidation Durvalumab Is Key in Stage III NSCLC

Sandip P. Patel, MD, discussed the real-world application of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.

Read the full article here

Related Articles